Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1

Conditions

Multiple Myeloma 74Lymphoma, Follicular 20Lymphoma, Large B-Cell, Diffuse 19Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Recurrence 7Smoldering Multiple Myeloma 6Lymphoma, B-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasms 5Lymphoma 5Lymphoma, Non-Hodgkin 4Burkitt Lymphoma 3Plasmacytoma 2Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Neurologic Manifestations 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, AIDS-Related 1Leukemia, Plasma Cell 1Leukemia 1Histiocytosis, Langerhans-Cell 1

Interventions

Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Erdheim-Chester Disease × Lenalidomide × Clear all
NCT02523040 2025-12-10

Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled 14 charts
MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡